Drug Profile

CD19 ARM

Alternative Names: CD19-ARM; CD19-ARM - Janux Therapeutics

Latest Information Update: 05 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Janux Therapeutics
Class Bispecific antibodies; Immunotherapies
Mechanism of Action CD19 antigen modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Autoimmune disorders

Most Recent Events

24 Jul 2025 Preclinical trials in Autoimmune disorders in USA (Parenteral), prior to July 2025
24 Jul 2025 Adverse events and pharmacodynamics data from a preclinical trials in Autoimmune disorders released by Janux Therapeutics
24 Jul 2025 Janux Therapeutics announced the intention to initiate a clinical trial in the first half of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com